555 Long Wharf Drive, 5th Floor
New Haven, CT 06511
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) is a clinical stage biopharmaceutical company focused on drug development utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The Company’s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
BioXcel Therapeutics has pioneered a novel approach to drug development. By leveraging the power of AI, we use mechanistic insights to identify multiple candidates, which are then further evaluated by our translational, clinical, and regulatory teams. Our process optimizes R&D economics, increases the probability of success, and shortens developmental timelines. This unique strategy grants us the opportunity to generate multiple NDAs.